Wells Fargo analyst Stan Berenshteyn raised the firm’s price target on HealthEquity to $110 from $107 and keeps an Overweight rating on the shares. The firm notes HealthEquity is +35% year-over-year vs S&P +25%, driven by estimate growth. Wells thinks a fair valuation with visible tailwinds equates to an attractive buying opportunity even if near term rate volatility is a concern.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity price target raised to $105 from $100 at Raymond James
- HealthEquity price target raised to $105 from $100 at Barrington
- HealthEquity price target raised to $104 from $98 at Baird
- HealthEquity price target raised to $105 from $97 at BofA
- HealthEquity price target raised to $105 from $101 at JMP Securities